Latest News
-
Monday - July 8, 2019
Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism
Phase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prevention of recurrent VTE in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis » more
-
Wednesday - July 3, 2019
Prestigious award from the Bayer Science & Education Foundation:
2019 Hansen Family Award goes to Professor Edith Heard
Professor Edith Heard, Director General of the European Molecular Biology Laboratory (EMBL) is awarded for groundbreaking insights into the field of epigenetics and its role in basic medical research » more
-
Tuesday - July 2, 2019
Data-Driven Tools from The Climate Corporation’s Climate FieldView™ Platform Now Available for Argentine Farmers:
Bayer expands industry-leading digital farming platform in Argentina » more
-
Tuesday - July 2, 2019
Not intended for U.S. Media
Bayer’s new SRD Smart Compare aids responsible antibiotic use in swine respiratory disease treatment
Novel online comparison tool puts solid efficacy data on swine respiratory treatments at veterinarians’ fingertips » more
-
Tuesday - July 2, 2019
LEO Pharma completes the acquisition of Bayer’s prescription dermatology business » more
-
Monday - July 1, 2019
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments » more
-
Friday - June 28, 2019
Experts discuss latest feline infectious disease threats at European congress
The 18th ISFM Congress welcomed parasitologists, veterinary clinicians and feline medicine experts to a first-class scientific programme exploring the latest findings in feline infectious diseases / The Bayer Symposium at the European congress investigated the growing threat of feline lungworm, with experts offering guidance on diagnosis and treatment » more
-
Wednesday - June 26, 2019
Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator » more
-
Wednesday - June 26, 2019
Not intended for U.S. and UK Media
Bayer will present new data on its hemophilia treatments at ISTH 2019 » more
-
Wednesday - June 26, 2019
Advocate® Spot-on receives positive CVMP opinion for new indications
Addition of three new therapeutic indications to the Advocate® product information for cats » more
-
Monday - June 24, 2019
Helping growers worldwide to control major pests:
Bayer and AlphaBio Control sign distribution agreement for innovative biological pest control product » more
-
Friday - June 21, 2019
Not intended for U.S. and UK Media
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants » more
-
Wednesday - June 19, 2019
Not intended for U.S. and UK Media
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
GBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as treatment options are limited and patient outcomes have remained largely unchanged over several decades » more
-
Friday - June 14, 2019
Bayer raises the bar in transparency, sustainability and engagement
With its solutions, the company aims to reduce environmental impact by 30 percent / Approximately 5 billion euros will be invested in additional methods to combat weeds over the next decade / Invitation to scientists, journalists and NGO representatives to participate in the scientific preparation for the upcoming EU glyphosate re-registration process / Crop protection products will only be sold in developing countries if they meet the standards of a majority of leading regulators on top of local regulations » more
-
Wednesday - June 5, 2019
Bayer at the ISF World Seed Congress 2019 in Nice, France:
Shaping agriculture through new seed varieties and innovative seed-applied technologies
Innovation and technologies make agriculture more productive and sustainable / NemaStrike™ Technology helps corn, soybean, and cotton farmers protect their yield / Bayer expands biological seed treatment portfolio with JumpStart™ and ProStablish™ » more
-
Tuesday - June 4, 2019
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Agreement worth more than USD 110 million includes the first-ever research application of Proteolysis-Targeting Chimera (PROTAC®) technology in agriculture / Bayer and Arvinas to launch joint venture to develop targeted protein degraders for agriculture applications / Collaboration agreement and equity investment by Bayer to develop next-generation medicines for patients with cardiovascular, oncological and gynecological diseases » more
-
Monday - June 3, 2019
Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019
In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with TRK fusion cancer with primary central nervous system (CNS) tumors (including high grade gliomas), the overall response rate was 36% including two complete responses / 71% of evaluable patients with primary CNS tumors experienced disease control for 24 weeks or more / First prospective analysis of the activity of larotrectinib in patients with TRK fusion cancer and intracranial disease, including first data ever presented for a TRK inhibitor in adult primary CNS TRK fusion cancer » more
-
Monday - June 3, 2019
Bayer Animal Health launches Advantage™ Spot-On in China
Advantage™ is a gentle, yet effective flea control for cats and dogs with a proven track record of more than 20 years / The brand is now available in China with its enormous increase in pet ownership and growth of urban populations » more
-
Friday - May 31, 2019
Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Bayer’s darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate cancer
Results of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delayed worsening of urinary and bowel symptoms versus placebo plus ADT / Exposure-adjusted incidences of treatment-emergent adverse events (TEAEs), including notably TEAEs associated with androgen receptor (AR) antagonists, were generally similar for darolutamide plus ADT compared to placebo plus ADT / Darolutamide plus ADT maintained quality of life in men with non-metastatic castration-resistant prostate cancer (nmCRPC) beyond end of study treatment with scores similar to placebo plus ADT / Analysis on quality of life related endpoints from pivotal Phase III ARAMIS trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation on May 31, 2019 / Darolutamide is under Priority Review in the U.S., and has been filed in Europe, Japan and additional countries » more
-
Wednesday - May 29, 2019
Not intended for U.S. and UK Media
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics (CDx) in oncology
Collaboration will start with development of a companion diagnostic for larotrectinib, the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors; larotrectinib is under review in other markets around the world / Goal is to advance broad patient access to comprehensive genomic testing in line with Bayer’s commitment to precision medicine » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Wednesday, October 30, 2019
Q3 2019 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV